STAT

From assisted hatching to embryo glue, most IVF ‘add-ons’ rest on shaky science, studies find

Women going through IVF are charged for "add-on" procedures such as endometrial scratching and assisted hatching "before they have been shown to improve the live birth rate,” said one expert.

By the time Sarah Chamberlin’s fertility doctor declared her genes “incompatible” with her husband’s and said the clash might be preventing her from having children, she’d had five rounds of artificial insemination and two cycles of in vitro fertilization — and precisely zero pregnancies. So when the physician suggested she try a drug that is ordinarily prescribed to cancer patients, to get her immune system to stop attacking her embryos, she didn’t hesitate.

“I was 41 by then,” said Chamberlain, 47, who lives on New York’s Long Island and at the time was a consultant at her husband’s restaurant. “When they say they have one more thing you can try, it gives you hope.”

She had already spent tens of thousands of dollars in an effort to conceive — her insurance didn’t cover assisted reproduction — and had grown inured to the fertility-related shots that turned her into a human pin cushion. With all she had been through, it seemed foolish to hesitate over six additional daily injections and another $3,000 for the drug, called Neupogen; the idea that she might finally have a baby was irresistible.

In the 40 years since

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Arguments, A Merck Drug Approval, And More
U.S. Supreme Court justices focused on plaintiffs' right to sue the FDA to reinstate restrictions on a commonly used abortion pill, suggesting they are unlikely to restrict access.
STAT1 min read
STAT+: New Gene Therapy, To Be Priced At $4.25 Million, Has Already Transformed Children’s Lives
The world's most expensive treatment offers a near-cure for young children and redemption for its developer, but steep challenges still loom.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CAR-T Drugs For Myeloma, CVS Rebate Credits, And More
A FDA panel voted in favor of expanding use of CAR-T therapy in multiple myeloma, despite concerns about side effects.

Related